Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Clearside Biomedical Inc Market Cap
Based on ratings from 7 stock analysts, the Clearside Biomedical Inc stock price is expected to increase by 500% in 12 months. This is calculated by using the average 12-month stock price forecast for Clearside Biomedical Inc. The lowest target is $5 and the highest is $8. Please note analyst price targets are not guaranteed and could be missed completely.
CLSD is a stock in Healthcare which has been forecasted to be worth $6 as an average. On the higher end, the forecast price is $8 USD by Annabel Samimy from Stifel and on the lower end CLSD is forecasted to be $5 by from Wedbush.
These are the latest 20 analyst ratings of CLSD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Daniil Gataulin Chardan Capital | Buy | $6 | Maintains | Nov 15, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $6 | Reiterates | Nov 14, 2024 |
| Serge Belanger Needham | Buy | $6 | Reiterates | Nov 13, 2024 |
| Daniil Gataulin Chardan Capital | Buy | $6 | Maintains | Oct 14, 2024 |
| Serge Belanger Needham | Buy | $6 | Maintains | Oct 10, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $5 | Reiterates | Aug 27, 2024 |
| Daniil Gataulin Chardan Capital | Buy | $6 | Initiates | Aug 21, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $5 | Reiterates | Aug 13, 2024 |
| Serge Belanger Needham | Buy | $4 | Reiterates | Aug 13, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $5 | Reiterates | Jul 30, 2024 |
| Serge Belanger Needham | Buy | $4 | Reiterates | Jul 25, 2024 |
| Andreas Argyrides Oppenheimer | Outperform | $5 | Initiates | Jun 25, 2024 |
| Serge Belanger Needham | Buy | $4 | Reiterates | May 13, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $5 | Maintains | May 13, 2024 |
Needham | Buy | $4 | Reiterates | Apr 11, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $6 | Reiterates | Mar 14, 2024 |
| Liana Moussatos Wedbush | Outperform | $4 | Maintains | Mar 13, 2024 |
| Serge Belanger Needham | Buy | $4 | Reiterates | Mar 13, 2024 |
| Jonathan Wolleben JMP Securities | Market Outperform | $5 | Reiterates | Mar 13, 2024 |
| Yi Chen HC Wainwright & Co. | Buy | $6 | Reiterates | Nov 14, 2023 |
When did it IPO
2016
Staff Count
30
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Market Cap
$75.8M
In 2023, CLSD generated $8.2M in revenue, which was a increase of 519.89% from the previous year. This can be seen as a signal that CLSD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Clearside Biomedical showcased its suprachoroidal delivery technology and pipeline programs at international medical meetings, reinforcing its leadership in the field.
Why It Matters - Clearside's advancements in suprachoroidal delivery technology and positive clinical results enhance its market position, potentially driving future revenue and investor interest.
Fri, 15 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Clearside Biomedical (CLSD) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects.
Why It Matters - An upgrade to Zacks Rank #2 (Buy) indicates increased confidence in Clearside Biomedical's earnings potential, suggesting potential stock price appreciation and attracting investors.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Clearside Biomedical will hold its Q3 2024 earnings call on November 12, 2024, at 4:30 PM ET, featuring key executives and analysts from various firms.
Why It Matters - The earnings call will provide insights into Clearside Biomedical's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Tue, 12 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Clearside Biomedical (CLSD) reported a quarterly loss of $0.10 per share, better than the estimated loss of $0.14, and an improvement from a loss of $0.15 per share a year prior.
Why It Matters - Clearside Biomedical's smaller-than-expected loss indicates improving financial performance and may boost investor confidence, potentially influencing stock price positively.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Clearside Biomedical's partnership with Arctic Vision and Santen Pharmaceutical aims to enhance treatment for posterior segment eye diseases in China, validating its SCS® delivery platform.
Why It Matters - The partnership expands Clearside's market reach in China, validating its SCS delivery platform and potentially boosting revenue from treatments for eye diseases.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Clearside Biomedical appointed Tony Gibney as Chair of its Board of Directors, effective November 1, 2024, succeeding Clay Thorp, who remains on the Board.
Why It Matters - The appointment of Tony Gibney as Chair may signal a strategic shift in leadership, potentially influencing Clearside's direction and investor confidence in its innovative eye therapies.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
